title: Identifying and ensuring optimal care for all children at risk of developing serious respiratory syncytial virus disease: a Canadian nurses' perspective.
abstract: Globally, respiratory syncytial virus (RSV) infection causes substantial morbidity in infants and young children, particularly those with specific risk factors (e.g., prematurity, chronic lung and congenital heart disease). Supportive measures are the mainstay of care for RSV-related disease. In the absence of medical treatments, RSV prophylaxis (RSVP) with palivizumab is recommended for high-risk patients to help reduce the risk of developing serious disease. Geographic distances, language and cultural barriers, and other factors can impede effective education of caregivers regarding the potential impact of RSV disease and benefits of RSVP compliance. We present our experiences developing successful Canadian RSVP programs, organized through a dedicated coordinator or small group of health care staff. These programs focus on identifying all infants and young children eligible for RSVP, effectively educating health care staff and family caregivers, developing educational tools that consider language and cultural factors, and interdisciplinary collaboration and networking throughout the health care system.
authors.affiliation: Neonatal Intensive Care Unit, Mount Sinai Hospital, 775 A-600 University Avenue, Toronto, Ontario M5G 1X5, Canada. mbracht@mtsinai.on.ca
authors.forename: Marianne
authors.initials: M
authors.lastname: Bracht
authors.forename: Debbie
authors.initials: D
authors.lastname: Basevitz
authors.forename: Marilyn
authors.initials: M
authors.lastname: Cranis
authors.forename: Rose
authors.initials: R
authors.lastname: Paulley
authors.forename: Bosco
authors.initials: B
authors.lastname: Paes
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001291:Attitude of Health Personnel; D002170:Canada / Q000453:epidemiology; D017028:Caregivers / Q000193:education; D002648:Child; D002675:Child, Preschool; D003144:Communication Barriers; D054521:Cultural Competency; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D055118:Medication Adherence; D000069455:Palivizumab; D017410:Practice Guidelines as Topic; D011314:Preventive Health Services / Q000379:methods / Q000458:organization & administration*; D016730:Program Development; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000209:etiology / Q000451:nursing / Q000517:prevention & control*; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab